Clinical trial · Interventional
Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma
Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma After Progression of PD-1/L1 Antibody Treatment: a Pilot Clinical Study
NCT06530784CI-TRIAL-00079311unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To explore the safety and efficacy of cryoablation combined with PD-1 antibody and bevacizumab for patients with hepatocellular carcinoma resistance to PD-1/L1 antibody.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Hepatocellular | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cryoablation | Procedure | — | UNRESOLVED |
| PD-1 antibody and bevacizumab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- treatment group
- description
- Cryoablation combined with PD-1 antibody and bevacizumab
- interventionNames
- Procedure: Cryoablation
- Drug: PD-1 antibody and bevacizumab
Primary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- Up to 2 years
- description
- mRECIST is used as the evaluation criterion for CT/MRI imaging at each follow-up visit.
Secondary outcomes (4)
- measure
- Time to progress
- timeFrame
- Up to 2 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age between 18 and 80 years old, and expected survival is longer than 3 months 2. Clinically or pathologically diagnosed as primary hepatocellular carcinoma 3. Disease progression assessed according to mRECIST criteria after PD-1/L1 antibody treatment 4. Child-Pugh score of liver function A/B (\< 7) 5. At least one lesion is suitable for mRECIST assessment 6. Strength score (ECOG): 0-1 7. The patient and/or family members agree to join the clinical trial and sign the informed consent form Exclusion Criteria: 1. Patients whose tumor lesions are not suitable for ablation as assessed by the surgeon 2. Tumor burden greater than ≥70%, or tumor is not suitable for mRECIST standard evaluation 3. Patients with chronic viral hepatitis (hepatitis B, hepatitis C) have a viral load greater than 10\^4 before receiving treatment or do not continue to take antiviral drugs regularly 4. Pregnant patients 5. Combined with other malignant tumors, or have a history of other malignant tumors within 3 years 6. Active autoimmune disease, confirmed immunodeficiency, history of systemic steroid medication 7. Severe renal dysfunction: creatinine (Cr) \> 2 mg/dL or creatinine clearance (CCr) \<30 mL/min, severe heart, lung, brain and other important organ diseases 8. History of gastrointestinal bleeding within 3 months 9. Unable to cooperate with ablation surgery 10. Severe gastroesophageal varices
References
Publications (0)
Data not yet available
No reference posted for this study.